Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

161 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Pharmacological properties and clinical development overview of pertuzumab (genetical recombination), trastuzumab (genetical recombination) and vorhyaluronidase alfa (genetical recombination) (PHESGO® combination for ‍subcutaneous injection MA, IN)].
Sakaeda M, Kotani N, Yoneya T, Zheng Y, Habara Y. Sakaeda M, et al. Among authors: kotani n. Nihon Yakurigaku Zasshi. 2024;159(4):241-253. doi: 10.1254/fpj.24022. Nihon Yakurigaku Zasshi. 2024. PMID: 38945908 Review. Japanese.
Clinical pharmacology of emicizumab for the treatment of hemophilia A.
Yoneyama K, Schmitt C, Portron A, Kiialainen A, Kotani N, Jaminion F, Retout S, Adamkewicz JI. Yoneyama K, et al. Among authors: kotani n. Expert Rev Clin Pharmacol. 2023 Jul-Dec;16(9):775-790. doi: 10.1080/17512433.2023.2243213. Epub 2023 Aug 21. Expert Rev Clin Pharmacol. 2023. PMID: 37529848 Free article. Review.
Proximity Labeling and Proteomics: Get to Know Neighbors.
Kotani N, Araki T, Miyagawa-Yamaguchi A, Amimoto T, Nakano M, Honke K. Kotani N, et al. Methods Enzymol. 2023;679:131-162. doi: 10.1016/bs.mie.2022.07.031. Epub 2022 Sep 2. Methods Enzymol. 2023. PMID: 36682860
Characterization of exposure-response relationships of ipatasertib in patients with metastatic castration-resistant prostate cancer in the IPATential150 study.
Kotani N, Wilkins JJ, Wade JR, Dang S, Sutaria DS, Yoshida K, Sundrani S, Ding H, Garcia J, Hinton H, Sane R, Chanu P. Kotani N, et al. Cancer Chemother Pharmacol. 2022 Dec;90(6):511-521. doi: 10.1007/s00280-022-04488-2. Epub 2022 Oct 28. Cancer Chemother Pharmacol. 2022. PMID: 36305957 Free PMC article.
Enzyme-mediated activation of radical sources (EMARS)-based molecular interaction analysis.
Kotani N, Yamaguchi A, Honke K. Kotani N, et al. 2021 Aug 11 [updated 2022 Mar 28]. In: Nishihara S, Angata K, Aoki-Kinoshita KF, Hirabayashi J, editors. Glycoscience Protocols (GlycoPODv2) [Internet]. Saitama (JP): Japan Consortium for Glycobiology and Glycotechnology; 2021–. 2021 Aug 11 [updated 2022 Mar 28]. In: Nishihara S, Angata K, Aoki-Kinoshita KF, Hirabayashi J, editors. Glycoscience Protocols (GlycoPODv2) [Internet]. Saitama (JP): Japan Consortium for Glycobiology and Glycotechnology; 2021–. PMID: 37590745 Free Books & Documents. Review. No abstract available.
161 results